Skip to main content

Current Extramural Funding

National Cancer Institute (NCI) NIH
1 R21 CA226489-01
An Exploratory Phase 1B Study to Assess the Effects of Merestinib on Bone Metastases in Subjects with Metastatic Breast Cancer
Adam L. Cohen, MD, and Alana I. Welm, PhD

National Institutes of Health (NIH)
1R01AG055428-01A1
Enriching Clinical Trials Requiring Amyloid Positivity with Practice Effects
John M. Hoffman, MD, and Kevin Duff, PhD

National Institutes of Health (NIH)
1R01NS092458-01
Causes, consequences, imaging and mitigation of sepsis-induced encephalopathy
John M. Hoffman, MD, Jeffrey T. Yap, PhD, and Kathryn Morton, MD

National Institutes of Health (NIH)
1R01HL135328-01A1
Quantitative MRI for Characterizing Heart Failure with Preserved Ejection Fraction
Edward DiBella, PhD

Previous Extramural Funding

National Cancer Institute (NCI) NIH
5U54CA168512
SARC Sarcoma SPORE
Jeffrey T. Yap, PhD

National Cancer Institute (NCI)
R21 CA150381
Preliminary Evaluation of FDG-PET with Anti-IGF-1R Targeted Therapy in GISTs
Jeffrey T. Yap, PhD

National Cancer Institute (NCI)
2R01CA135556-05
Multi-Tracer PET Tumor Imaging
Dan Kadrmas, PhD

National Institutes of Health (NIH)
1R01HL113224-01A1
Quantitative cardiac MRI perfusion for longitudinal studies
Edward DiBella, PhD

National Institutes of Health (NIH)
1R21CA182977
Multi-Tracer PET/CT Imaging of Gemcitabine Response in Pancreatic Cancer
Dan Kadrmas, PhD

National Cancer Institute (NIH)
1-R21 CA167795-01
Multi-Tracer PET Assessment of Response to Novel Targeted Chemotherapy
John M. Hoffman, MD (Morton Co-PI)

National Comprehensive Cancer Network (NCCN)
Sunitinib for Metastatic Renal Cell Cancer with Imaging Biomarker Assessments for the Early Prediction of Tumor Response
John M. Hoffman, MD

National Cancer Institute (NIH)
1 R01 CA135556-01A1
Multi-Tracer PET Tumor Imaging
Dan J. Kadrmas, PhD

National Cancer Institute (NIH)
1-R21-CA128228-01
FDG-PET/CT in the evaluation of persistent febrile neutropenia in cancer patients
John M. Hoffman, MD

National Institute of Biomedical Imaging and Bioengineering (NIH)
2 R01 EB000177-05
Dynamic MRI for Myocardial Perfusion and Viability
Edward V. DiBella, PhD

University of Utah Synergy Grant Program
Development of an Integrated Molecular Biomarker of Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients using Imaging Assessments and Genomic Modeling
John M. Hoffman, MD

National Cancer Institute (NIH)
R01 CA121003-01
FDG PET in cancer-associated venothromboembolic disease
Kathryn A. Morton, MD

National Center for Research Resources (NCRR) (NIH)
1S10RR023017-01
Utah Small Animal MRI Research Resource
Edward Hsu, PhD

Margolis Foundation
Programmatic Support for Initial Studies to Validate a New Radiotracer to Image Amyloid Plaques In Vivo Synthesized at the Cyclotron Facility at the University of Utah
Norman Foster, MD

National Institute of Biomedical Imaging and Bioengineering (NIH)
R21 EB005728-01
Imaging phenotypes in copper metabolism disease in mice
Kathryn A. Morton, MD

Contact Us

Center for Quantitative Cancer Imaging Director
Jeffrey Yap, PhD
jeffrey.yap@hci.utah.edu
801-213-5650

Senior Advisor to the Director
John M. Hoffman, MD
john.hoffman@hci.utah.edu
801-587-4064

Governance

HCI Senior Director Oversight
David Gaffney, MD, PhD